HIV pills and new lung drugs keep GSK on track in third-quarter
LONDON (Reuters) – GlaxoSmithKline <GSK.L> grew sales 4 percent in the third quarter, helped by demand for new products, keeping it on track to deliver on full-year financial targets as new Chief Executive Emma Walmsley refocuses the drugs pipeline.
Britain’s biggest drugmaker reported a 3 percent rise in adjusted earnings per share to 32.5 pence on sales of 7.84 billion pounds. Analysts, on average, had forecast 31.8p and 7.88 billion pounds, according to Thomson Reuters data.
(Reporting by Ben Hirschler; Editing by Tom Bergin)